Previous close | 50.75 |
Open | 50.93 |
Bid | 49.60 x 100 |
Ask | 50.44 x 100 |
Day's range | 49.52 - 50.93 |
52-week range | 12.45 - 67.21 |
Volume | |
Avg. volume | 214,518 |
Market cap | 856.93M |
Beta (5Y monthly) | 2.88 |
PE ratio (TTM) | N/A |
EPS (TTM) | -18.69 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 135.00 |
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,800 shares of its common stock and r
The consensus price target hints at a 144.7% upside potential for Praxis Precision Medicines (PRAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremorBOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations of two abstracts showca